New semiphysiological absorption model to assess the pharmacodynamic profile of cefuroxime axetil using nonparametric and parametric population pharmacokinetics

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 8, 2009, Pages 3462-3471

  Bulitta, J B ^a,d   Landersdorfer, C B ^a,d   Kinzig, M ^a   Holzgrabe, U ^b   Sorgel, F ^a,c  

^a IBMP Institute for Biomedical and Pharmaceutical Research   (Germany)

^b UNIVERSITY OF WÜRZBURG   (Germany)

^c UNIVERSITY OF DUISBURG ESSEN   (Germany)

^d ORDWAY RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFUROXIME; CEFUROXIME AXETIL; PENICILLIN G;

ADULT; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIOSTASIS; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG RELEASE; HUMAN; HUMAN EXPERIMENT; LIQUID CHROMATOGRAPHY; MALE; MINIMUM INHIBITORY CONCENTRATION; MONTE CARLO METHOD; NORMAL HUMAN; PRIORITY JOURNAL; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS PYOGENES; TANDEM MASS SPECTROMETRY;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; CEFUROXIME; CHROMATOGRAPHY, LIQUID; HUMANS; MALE; MODELS, THEORETICAL; TANDEM MASS SPECTROMETRY; TIME FACTORS; YOUNG ADULT;

EID: 67749114556     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00054-09     Document Type: Article

References (56)

1. Alvarez-Sala, J. L., P. Kardos, J. Martinez-Beltran, P. Coronel, and L. Aguilar. 2006. Clinical and bacteriological efficacy in treatment of acute exacerbations of chronic bronchitis with cefditoren-pivoxil versus cefuroxime-axetil. Antimicrob. Agents Chemother. 50:1762-1767.
2. Ambrose, P. G., S. M. Bhavnani, R. N. Jones, W. A. Craig, and M. N. Dudley. 2004. Use of pharmacokinetic-pharmacodynamic and Monte-Carlo simulation as decision support for the re-evaluation of NCCLS cephem susceptibility breakpoints for Enterobacteriaceae. Abstr. 44th Intersci. Conf. Antimicrob. Agents Chemother., abstr. A-138.
3. Ambrose, P. G., S. M. Bhavnani, C. M. Rubino, A. Louie, T. Gumbo, A. Forrest, and G. L. Drusano. 2007. Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore. Clin. Infect. Dis. 44:79-86.
4. Bauer, R. J. 2007. S-ADAPT/MCPEM user's guide (version 1.55). Software for pharmacokinetic, pharmacodynamic and population data analysis. Biomedical Simulations Resource, Berkeley, CA.
5. Beal, S. L., L. B. Sheiner, and A. J. Boeckmann. 2006. NONMEM user's guides (1989 to 2006). Icon Development Solutions, Ellicott City, MD.
6. Bouchillon, S. K., D. J. Hoban, J. L. Johnson, B. M. Johnson, D. L. Butler, K. A. Saunders, L. A. Miller, and J. A. Poupard. 2004. In vitro activity of gemifloxacin and contemporary oral antimicrobial agents against 27,247 Gram-positive and Gram-negative aerobic isolates: a global surveillance study. Int. J. Antimicrob. Agents 23:181-196.
7. Brauers, J., S. Bagel, and M. Kresken. 2005. Aktuelle Resistenzsituation bei bakteriellen Erregern von ambulant erworbenen Atemwegsinfektionen. Chemother. J. 14:45-53.
8. British Society for Antimicrobial Chemotherapy. 2008. BSAC methods for antimicrobial susceptibility testing, version 7.1. British Society for Antimicrobial Chemotherapy, Birmingham, United Kingdom.
9. Bulitta, J., C. Landersdorfer, M. Kinzig-Schippers, V. Jakob, M. Rodamer, G. L. Drusano, U. Thyroff-Friesinger, U. Holzgrabe, and F. Sörgel. 2006. Abstr. 46th Intersci. Conf. Antimicrob. Agents Chemother., poster A-1119.
10. Bulitta, J. B., S. B. Duffull, M. Kinzig-Schippers, U. Holzgrabe, U. Stephan, G. L. Drusano, and F. Sorgel. 2007. Systematic comparison of the population pharmacokinetics and pharmacodynamics of piperacillin in cystic fibrosis patients and healthy volunteers. Antimicrob. Agents Chemother. 51:2497-2507.
11. Chodosh, S., J. McCarty, S. Farkas, M. Drehobl, R. Tosiello, M. Shan, L. Aneiro, S. Kowalsky, et al. 1998. Randomized, double-blind study of cipro-floxacin and cefuroxime axetil for treatment of acute bacterial exacerbations of chronic bronchitis. Clin. Infect. Dis. 27:722-729.
12. Clinical and Laboratory Standards Institute. 2007. Performance standards for antimicrobial susceptibility testing; 17th informational supplement, vol. 27. Clinical and Laboratory Standards Institute, Wayne, PA.
13. Craig, W. A. 2003. Basic pharmacodynamics of antibacterials with clinical applications to the use of beta-lactams, glycopeptides, and linezolid. Infect. Dis. Clin. N. Am. 17:479-501.
14. Craig, W. A. 1998. Choosing an antibiotic on the basis of pharmacodynamics. Ear Nose Throat J. 77:7-12.
15. Craig, W. A. 1998. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin. Infect. Dis. 26:1-12.
16. Dagan, R., O. Abramson, E. Leibovitz, D. Greenberg, R. Lang, S. Goshen, P. Yagupsky, A. Leiberman, and D. M. Fliss. 1997. Bacteriologic response to oral cephalosporins: are established susceptibility breakpoints appropriate in the case of acute otitis media? J. Infect. Dis. 176:1253-1259.
17. de Abate, C. A., R. A. McIvor, P. McElvaine, et al. 1999. Smokers treated with gatifloxacin had a high clinical cure rate: gatifloxacin vs. cefuroxime axetil in patients with acute exacerbations of chronic bronchitis. J. Respir. Dis. 20(Suppl.):S23-S29.
18. Deutsches Institut für Normung e.V. 2004. Medizinische Mikrobiologie-Empfindlichkeitsprüfung von mikrobiellen Krankheitserregern gegen Chemotherapeutika-Teil 4: Bewertungsstufen für die minimale Hemmkonzentration-MHK-Grenzwerte von antibakteriellen Wirkstoffen. DIN 58940-4. Beuth Verlag, Berlin, Germany.
19. Drusano, G. L. 2004. Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'. Nat. Rev. Microbiol. 2:289-300.
20. File, T. M., Jr., J. Segreti, L. Dunbar, R. Player, R. Kohler, R. R. Williams, C. Kojak, and A. Rubin. 1997. A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with communityacquired pneumonia. Antimicrob. Agents Chemother. 41:1965-1972.
21. Finn, A., A. Straughn, M. Meyer, and J. Chubb. 1987. Effect of dose and food on the bioavailability of cefuroxime axetil. Biopharm. Drug Dispos. 8:519-526.
22. Foord, R. D. 1976. Cefuroxime: human pharmacokinetics. Antimicrob. Agents Chemother. 9:741-747.
23. Garraffo, R., H. B. Drugeon, and D. Chiche. 1997. Pharmacokinetics and pharmacodynamics of two oral forms of cefuroxime axetil. Fundam. Clin. Pharmacol. 11:90-95.
24. Hara, T., H. Saeki, A. Yamamoto, K. Ohta, T. Suzuki, M. Ara, M. Sugawara, Y. Sano, H. Sakuma, and K. Satoh. 1988. Concentrations of cefuroxime in the skin. Jpn. J. Antibiot. 41:10-17.
25. Higaki, K., S. Y. Choe, R. Lobenberg, L. S. Welage, and G. L. Amidon. 2008. Mechanistic understanding of time-dependent oral absorption based on gastric motor activity in humans. Eur. J. Pharm. Biopharm. 70:313-325.
26. Hoban, D. J., S. K. Bouchillon, J. L. Johnson, G. G. Zhanel, D. L. Butler, K. A. Saunders, L. A. Miller, and J. A. Poupard. 2003. Comparative in vitro potency of amoxycillin-clavulanic acid and four oral agents against recent North American clinical isolates from a global surveillance study. Int. J. Antimicrob. Agents 21:425-433.
27. Hoban, D. J., S. K. Bouchillon, J. L. Johnson, G. G. Zhanel, D. L. Butler, K. A. Saunders, L. A. Miller, and J. A. Poupard. 2003. Comparative in vitro surveillance of amoxicillin-clavulanic acid and four oral comparators against 21232 clinical isolates from europe. Eur. J. Clin. Microbiol. Infect. Dis. 22:261-267.
28. Ison, C. A., J. W. Mouton, K. Jones, K. A. Fenton, and D. M. Livermore. 2004. Which cephalosporin for gonorrhoea? Sex. Transm. Infect. 80:386-388.
29. Jacobs, M. R. 2003. How can we predict bacterial eradication? Int. J. Infect. Dis. 7(Suppl. 1):S13-S20.
30. Jacobs, M. R., S. Bajaksouzian, A. Zilles, G. Lin, G. A. Pankuch, and P. C. Appelbaum. 1999. Susceptibilities of Streptococcus pneumoniae and Haemophilus influenzae to 10 oral antimicrobial agents based on pharmacodynamic parameters: 1997 U.S. surveillance study. Antimicrob. Agents Chemother. 43:1901-1908.
31. Jorgensen, A. F., J. Coolidge, P. A. Pedersen, K. P. Petersen, S. Waldorff, and E. Widding. 1992. Amoxicillin in treatment of acute uncomplicated exacerbations of chronic bronchitis. A double-blind, placebo-controlled multicentre study in general practice. Scand. J. Prim. Health Care 10:7-11.
32. Koeth, L. M., D. Felmingham, M. R. Jacobs, and F. Rossi. 2004. Antimicrobial resistance of Streptococcus pneumoniae and Haemophilus influenzae in Sao Paulo, Brazil from 1996 to 2000. Int. J. Antimicrob. Agents 23:356-361.
33. Kong, F., and R. P. Singh. 2008. A model stomach system to investigate disintegration kinetics of solid foods during gastric digestion. J. Food Sci. 73:E202-E210.
34. Leary, R., R. W. Jelliffe, A. Schumitzky, and M. Van Guilder. 2001. An adaptive grid non-parametric approach to pharmacokinetic and dynamic (PK/PD) models. IEEE Computer Society, Bethesda, MD.
35. Lesmana, M., C. I. Lebron, D. Taslim, P. Tjaniadi, D. Subekti, M. O. Wasfy, J. R. Campbell, and B. A. Oyofo. 2001. In vitro antibiotic susceptibility of Neisseria gonorrhoeae in Jakarta, Indonesia. Antimicrob. Agents Chemother. 45:359-362.
36. Llanes, R., J. Sosa, D. Guzman, A. Llop, E. A. Valdes, I. Martinez, S. Palma, and M. I. Lantero. 2003. Antimicrobial susceptibility of Neisseria gonorrhoeae in Cuba (1995-1999): implications for treatment of gonorrhea. Sex. Transm. Dis. 30:10-14.
37. Mackay, J., A. E. Mackie, J. L. Palmer, A. Moult, and N. S. Baber. 1992. Investigations into the mechanism for the improved oral systemic bioavailability of cefuroxime from cefuroxime axetil when taken after food (proceedings of the BPS, Sept. 1991). Br. J. Clin. Pharmacol. 33:226P-227P.
38. Mason, E. O., Jr., L. B. Lamberth, N. L. Kershaw, B. L. Prosser, A. Zoe, and P. G. Ambrose. 2000. Streptococcus pneumoniae in the USA: in vitro susceptibility and pharmacodynamic analysis. J. Antimicrob. Chemother. 45:623-631.
39. Morrissey, I., M. Robbins, L. Viljoen, and D. F. Brown. 2005. Antimicrobial susceptibility of community-acquired respiratory tract pathogens in the UK during 2002/3 determined locally and centrally by BSAC methods. J. Antimicrob. Chemother. 55:200-208.
40. Mouton, J. W., M. N. Dudley, O. Cars, H. Derendorf, and G. L. Drusano. 2005. Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update. J. Antimicrob. Chemother. 55:601-607.
41. Peric, M., F. A. Browne, M. R. Jacobs, and P. C. Appelbaum. 2003. Activity of nine oral agents against gram-positive and gram-negative bacteria encountered in community-acquired infections: use of pharmacokinetic/ pharmacodynamic breakpoints in the comparative assessment of beta-lactam and macrolide antimicrobial agents. Clin. Ther. 25:169-177.
42. Perry, C. M., and R. N. Brogden. 1996. Cefuroxime axetil. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy. Drugs 52:125-158.
43. Ruiz-Balaguer, N., A. Nacher, V. G. Casabo, and M. Merino. 1997. Nonlinear intestinal absorption kinetics of cefuroxime axetil in rats. Antimicrob. Agents Chemother. 41:445-448.
44. Ruiz-Balaguer, N., A. Nacher, V. G. Casabo, and M. Merino Sanjuan. 2002. Intestinal transport of cefuroxime axetil in rats: absorption and hydrolysis processes. Int. J. Pharm. 234:101-111.
45. Ruiz-Carretero, P., M. Merino-Sanjuan, A. Nacher, and V. G. Casabo. 2004. Pharmacokinetic models for the saturable absorption of cefuroxime axetil and saturable elimination of cefuroxime. Eur. J. Pharm. Sci. 21:217-223.
46. Scott, L. J., D. Ormrod, and K. L. Goa. 2001. Cefuroxime axetil: an updated review of its use in the management of bacterial infections. Drugs 61:1455-1500.
47. Sethi, S., and T. F. Murphy. 2004. Acute exacerbations of chronic bronchitis: new developments concerning microbiology and pathophysiology-impact on approaches to risk stratification and therapy. Infect. Dis. Clin. N. Am. 18:861-882.
48. Shah, P. M., F. P. Maesen, A. Dolmann, N. Vetter, E. Fiss, and R. Wesch. 1999. Levofloxacin versus cefuroxime axetil in the treatment of acute exacerbation of chronic bronchitis: results of a randomized, double-blind study. J. Antimicrob. Chemother. 43:529-539.
49. Stoeckel, K., W. L. Hayton, and D. J. Edwards. 1995. Clinical pharmacokinetics of oral cephalosporins. Antibiot. Chemother. 47:34-71.
50. Upchurch, J., M. Rosemore, R. Tosiello, S. Kowalsky, and R. Echols. 2006. Randomized double-blind study comparing 7- and 10-day regimens of faropenem medoxomil with a 10-day cefuroxime axetil regimen for treatment of acute bacterial sinusitis. Otolaryngol. Head Neck Surg. 135:511-517.
51. Vasu, S., C. Adithan, C. H. Shashindran, M. Asad, K. Koumaravelou, and I. Topno. 2000. Effect of two types of Indian breakfast on bioavailability of cefuroxime axetil. Indian J. Med. Res. 112:104-108.
52. Viberg, A., O. Cars, M. O. Karlsson, and S. Jonsson. 2008. Estimation of cefuroxime dosage using pharmacodynamic targets, MIC distributions, and minimization of a risk function. J. Clin. Pharmacol. 48:1270-1281.
53. Viberg, A., A. Lannergard, A. Larsson, O. Cars, M. O. Karlsson, and M. Sandstrom. 2006. A population pharmacokinetic model for cefuroxime using cystatin C as a marker of renal function. Br. J. Clin. Pharmacol. 62:297-303.
54. Weitschies, W., C. Friedrich, R. S. Wedemeyer, M. Schmidtmann, O. Kosch, M. Kinzig, L. Trahms, F. Sorgel, W. Siegmund, S. Horkovics-Kovats, F. Schwarz, J. Raneburger, and H. Monnikes. 2008. Bioavailability of amoxicillin and clavulanic acid from extended release tablets depends on intragastric tablet deposition and gastric emptying. Eur. J. Pharm. Biopharm. 70:641-648.
55. Williams, P. E., and S. M. Harding. 1984. The absolute bioavailability of oral cefuroxime axetil in male and female volunteers after fasting and after food. J. Antimicrob. Chemother. 13:191-196.
56. Zhanel, G. G., L. Palatnick, K. A. Nichol, D. E. Low, and D. J. Hoban. 2003. Antimicrobial resistance in Haemophilus influenzae and Moraxella catarrhalis respiratory tract isolates: results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002. Antimicrob. Agents Chemother. 47:1875-1881.